6 active not recruiting, 5 completed, 4 terminated, 3 unknown. 21 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Active not recruiting 6, Completed 5, Terminated 4, Unknown 3, Recruiting 2, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Recruiting 1 |
Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma Camrelizumab Combined With Apatinib - PD-1 Immunotherapy, VEGFR-TKI | Phase 2 | Unknown | Fudan University | 45 | 2021-11-21 | 2022-03-04 |
| ZW25 in Women With Endometrial Cancers ZW25 - Endometrial Cancer, Carcinosarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 16 | 2020-08-12 | 2025-05-22 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss Ceralasertib, Olaparib, Durvalumab - Gynaecological Cancers | Phase 2 | Active not recruiting | Institute of Cancer Research, United Kingdom | 174 | 2019-11-27 | 2026-02-20 |
| Nivolumab for Recurrent/Metastatic Carcinosarcoma nivolumab - Recurrent/Metastatic Carcinosarcoma | Phase 2 | Unknown | Yonsei University | 28 | 2019-11-13 | 2022-02-04 |
| Pazopanib Vs. Pazopanib Plus Gemcitabine Pazopanib plus Gemcitabine, Pazopanib - Leiomyosarcoma or Carcinosarcoma | Phase 2 | Active not recruiting | North Eastern German Society of Gynaecological Oncology | 58 | 2019-10-16 | 2024-11-15 |
| Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy Pamiparib - Ovarian Cancer, Carcinosarcoma | Phase 2 | Withdrawn | Australia New Zealand Gynaecological Oncology Group | 2019-07-29 | 2021-08-10 | |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Rebastinib, Paclitaxel - Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Deciphera Pharmaceuticals, LLC | 177 | 2018-10-25 | 2024-12-27 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 288 | 2018-09-27 | 2026-11-13 |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Paclitaxel, Cediranib, Olaparib - Carcinosarcoma, Endometrial Neoplasms | Phase 2 | Unknown | University of Manchester | 124 | 2018-05-17 | 2022-03-02 |
| Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 82 | 2018-04-16 | 2026-11-13 |
| A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma Paclitaxel, 300mg DKN-01, 600mg DKN-01 - Endometrial Cancer, Uterine Cancer | Phase 2 | Completed | Leap Therapeutics, Inc. | 111 | 2018-03-05 | 2025-08-01 |
| A Study of Nivolumab in Selected Uterine Cancer Patients Nivolumab - Uterine Cancer, Endometrial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2017-08-03 | 2024-12-27 |
| Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Trabectedin - Carcinosarcoma, Ovarian, Carcinosarcomas Uterine | Phase 2 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 45 | 2017-02-22 | 2021-08-25 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors PegLiposomal Doxorubicin, Carboplatin - Mesenchymal Tumor, Carcinosarcoma | Phase 2 | Completed | AGO Study Group | 41 | 2008-06-01 | 2017-02-14 |
Showing 20 of 21. Sign in to see all of them.
Endometrial Neoplasms (9) · Leiomyosarcoma (5) · Ovarian Neoplasms (5) · Uterine Cervical Neoplasms (4) · Uterine Neoplasms (4) · Carcinoma, Endometrioid (3) · Fallopian Tube Neoplasms (3) · Neoplasm Metastasis (3) · Vulvar Neoplasms (3) · Adenocarcinoma, Clear Cell (2) · Adenocarcinoma, Mucinous (2) · Breast Neoplasms (2) · Carcinoma, Adenoid Cystic (2) · Carcinoma, Transitional Cell (2)
Neoplasms by Histologic Type (21) · Neoplasms, Complex and Mixed (21) · Neoplasms, Connective and Soft Tissue (21) · Neoplasms (20) · Sarcoma (19) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Genital Neoplasms, Female (15) · Neoplasms by Site (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15) · Uterine Diseases (11) · Adnexal Diseases (9)
Nivolumab (5) · Paclitaxel (4) · Specimen Handling (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · olaparib (3) · Carboplatin (2) · Immunoglobulin G (2) · cediranib (2) · durvalumab (2) · Axitinib (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (2) · AGO Study Group (1) · Australia New Zealand Gynaecological Oncology Group (1) · Centre Oscar Lambret (1) · Deciphera Pharmaceuticals, LLC (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fudan University (1) · Incyte Corporation (1) · Institute of Cancer Research, United Kingdom (1) · Instituto do Cancer do Estado de São Paulo (1) · Leap Therapeutics, Inc. (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · North Eastern German Society of Gynaecological Oncology (1)
United States (10) · Canada (3) · United Kingdom (3) · Germany (2) · Brazil (1) · China (1) · France (1) · Guam (1) · Italy (1) · South Korea (1)
Alexander Mustea, Prof. Dr. med. (1) · Alison Freimund (1) · Camila MV Moniz, Doctor (1) · Claire Friedman, MD (1) · Cynthia Sirard (1) · Domenica Lorusso, Prof. (1) · Gordon Jayson (1) · Helen J Mackay (1) · Kim Reiss-Binder, MD (1) · Lois M. Ramondetta, MD (1) · Philipp Harter, MD (1) · Philomena Colucci (1) · Sandip P Patel (1) · Stephanie Lheureux (1)
PMID 10655437, PMID 11063636, PMID 11304695, PMID 11479630, PMID 15350372, PMID 15721404, PMID 16271748, PMID 17290061, PMID 17395252, PMID 17822748, PMID 17936342, PMID 18378136, PMID 18755503, PMID 23397080, PMID 23410977, PMID 25341582, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 34904813, PMID 35288469, PMID 37001446, PMID 38127487, PMID 38243705, PMID 38262242, PMID 38358334, PMID 38653864, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40632975, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42339309, PMID 42499790
2016 (1), 2018 (1), 2023 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186644 (1)